Savara Q2 Loss Widens on Commercial Build-Out; FDA Extends MOLBREEVI Review to November

summarizeSummary

Savara reported a wider Q2 loss as it ramps up commercial preparations for MOLBREEVI, while the FDA extended its review of the drug to November 2026. The company ended the quarter with $173 million in cash and investments.

check_boxKey Events · Earnings and Guidance · SVRA

• Q2 Net Loss Widens

  Net loss increased to $40.2M from $30.4M in Q2 2025, driven by a 78% jump in G&A expenses to $19.0M as the company builds its commercial infrastructure.

• Cash Burn Accelerates

  Cash used in operations was $62.8M in H1 2026, up from $53.5M a year ago. Cash and investments fell to $173.0M from $235.7M at year-end 2025.

• FDA Extends MOLBREEVI Review

  The FDA pushed the PDUFA date to November 22, 2026, after deeming the company's responses to information requests a major amendment, adding three months to the review.

• Former CFO Consulting Agreement

  David Lowrance, who stepped down as CFO in July 2026, entered a consulting agreement to support finance, HR, and facilities transition through the headquarters relocation.

auto_awesomeAnalysis · SVRA · Life Sciences

Savara's Q2 net loss jumped to $40.2 million from $30.4 million a year ago, driven by a 78% surge in G&A spending as the company aggressively staffs its commercial team ahead of a potential MOLBREEVI launch. The cash burn is significant — $62.8 million in the first half of 2026 — but the company still holds $173 million in cash and investments, providing runway into the expected FDA decision. The FDA's three-month review extension to November 22, 2026, adds uncertainty, though the agency's request for additional information does not necessarily signal a negative outcome. The consulting agreement with the former CFO formalizes his transition and ensures continuity in finance and operations during a critical pre-commercial period.